Abstract:Background: Targeted magnetic resonance contrast agents have enabled the imaging of biological processes in vivo, and current insights have opened up new perspectives for the monitoring and diagnosis of many diseases. Purpose: To develop a contrast agent for targeting somatostatin receptors (SSTRs) expressed on breast cancer cells, and to evaluate the detection capabilities of a molecular probe using magnetic resonance (MR) imaging in an in vivo mouse model of breast carcinoma. Material and Methods: Octreotide (OCT) was conjugated with polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles by an ethyl-3-(dimethylaminopropyl) carbodiimide (EDC)-mediated reaction. Prussian blue staining for intracellular iron, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cellular MR imaging in vitro were performed on labeled MCF-7 breast cancer cells. Twenty-four mice bearing tumors were divided into two groups: 1) study group with injection of OCT-USPIOs ( n=12); 2) control group with injection of USPIOs ( n=12). Tumors were monitored in vivo using a 3.0-Tesla MR scanner before and after injection of contrast agents, and the findings were correlated with the histopathological findings. Results: OCT-USPIOs were shown to specifically bind to MCF-7 cells and did not affect proliferation and viability of the cells labeled. T 2 value of the cells labeled with OCT-USPIOs in vitro was 56.465±13.147 ms, while those of the cells cultured with USPIOs and gelatin/phosphate-buffered saline (PBS) gel alone were 75.435±16.171 ms and 85.950±22.352 ms, respectively ( P<0.05). Signal intensity of the tumor gradually decreased, and its T 2 value reached a minimum of approximately 24.49% 6 hours after injection of OCT-USPIOs in vivo, compared to a minimum of 21.89% after 2 hours in the control group. Iron depositions were visualized as blue particles in tumor 6 hours after injection of OCT-USPIOs, while no blue particles were observed in the control group. Conclusion: SSTR expression in vitro and in vivo can be selectively and directly imaged with an MR molecular probe. OCT-conjugated PEG-coated USPIO is potentially suitable to be used as a magnetic resonance contrast agent for MR imaging in vivo and increases the sensitivity for the early detection of breast carcinoma.

Recent development in targeted MRI negative contrast based on ultra-small superparamagnetic iron oxide particles

Magnetic Resonance Imaging Contrast Agent: Crgd-Ferric Oxide Nanometer Particle and Its Role in the Diagnosis of Tumor

Ultrasmall Superparamagnetic Iron Oxide Nanoparticles: A Next Generation Contrast Agent for Magnetic Resonance Imaging

Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent.

Construction of cRGD-iron oxide nanoparticles and its application in the tumor diagnosis by magnetic resonance imaging

Gadolinium-based contrast agents for tumor targeting imaging

Preparation and Performance Study on Ultrasmall Superparamagnetic Iron Oxide(uspio) Nanoparticles

Carboxylated superparamagnetic Fe3O4 nanoparticles modified with 3-amino propanol and their application in magnetic resonance tumor imaging

Preparation and characterization of peptide modified ultrasmall superparamagnetic iron oxides used as tumor targeting MRI contrast agent

Application of superparamagnetic iron oxide nanoparticles in magnetic resonance imaging and drug delivery system

Octapod iron oxide nanoparticles as high-performance T 2 contrast agents for magnetic resonance imaging

Paramagnetic and Superparamagnetic Inorganic Nanoparticles for T1-Weighted Magnetic Resonance Imaging.

Research Status of Targeted Iron Oxide Magnetic Nanoparticles Used As Probe for Imaging of Tumor

Positive Contrast Imaging of SPIO Nanoparticles

Peptide-Decorated Ultrasmall Superparamagnetic Nanoparticles As Active Targeting MRI Contrast Agents for Ovarian Tumors

Iron Oxide Nanoparticles in the Application of Magnetic Resonance Imaging

Superparamagnetic Iron Oxide Nanoparticles for MR Imaging of Pancreatic Cancer: Potential for Early Diagnosis Through Targeted Strategies

Targeted Magnetic Iron Oxide Nanoparticles for Tumor Imaging and Therapy

Citric acid coated ultrasmall superparamagnetic iron oxide nanoparticles conjugated with lactoferrin for targeted negative MR imaging of glioma

Recent Advances In Superparamagnetic Iron Oxide Nanoparticles For Cellular Imaging And Targeted Therapy Research

Specific Targeting of Breast Tumor by Octreotide-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner